Featured Articles

Regeneron Pharmaceuticals, Inc. and Mammoth Biosciences, Inc., announced a collaboration to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple…
Read More...

Novartis announced that the U.S. Food and Drug Administration (FDA) approved Lutathera (USAN: lutetium Lu 177 dotatate / INN: lutetium (177Lu) oxodotreotide) for the treatment of…
Read More...

Ipsen and Skyhawk Therapeutics announced the signing of an exclusive worldwide collaboration to discover and develop novel small molecules that modulate RNA for rare neurological…
Read More...

Pfizer Inc. announced that the European Commission (EC) has granted marketing authorization for EMBLAVEO (aztreonam-avibactam) for the treatment of adult patients with complicated…
Read More...

Evotec SE and Variant Bio, Inc. announced a collaboration agreement to identify a best-in-class treatment for diseases caused by fibrosis. Fibrosis is characterised by marked and…
Read More...

Pfizer Inc. announced positive top-line immunogenicity and safety data from the ongoing pivotal Phase 3 clinical trial (NCT05842967) MONeT (RSV IMmunizatiON Study for AdulTs at Higher…
Read More...

AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+)…
Read More...

Bristol Myers Squibb and 2seventy bio, Inc. have announced that on April 4, 2024, the U.S. Food and Drug Administration (FDA) approved Abecma (idecabtagene vicleucel; ide-cel) for the…
Read More...

Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved CARVYKTI (ciltacabtagene autoleucel; cilta-cel) for the treatment of adult patients with…
Read More...

Lonza, a global manufacturing partner to the pharmaceutical, biotech and nutraceutical markets, announced it has signed an agreement to acquire the Genentech large-scale biologics…
Read More...

Bristol Myers Squibb announced that the European Commission (EC) has granted approval to Abecma (idecabtagene vicleucel; ide-cel) for the treatment of adult patients with relapsed and…
Read More...

Boehringer Ingelheim announced that the US Food and Drug Administration (FDA) has approved SPEVIGO (spesolimab-sbzo) injection for the treatment of generalized pustular psoriasis (GPP)…
Read More...

Almirall, S.A. and Eloxx Pharmaceuticals, Inc. announced that the companies have entered into an exclusive license agreement for the asset ZKN-013. Under the agreement, Almirall obtains…
Read More...

Pfizer Inc. announced that the European Commission (EC) has granted marketing authorization for the company’s 20-valent pneumococcal conjugate vaccine, marketed in the European Union…
Read More...

Merck, known as MSD outside of the United States and Canada, announced the completion of the acquisition of Harpoon Therapeutics, Inc. (Nasdaq: HARP). Harpoon is now a wholly-owned…
Read More...

Johnson & Johnson announced it has successfully completed the acquisition of Ambrx Biopharma, Inc., a clinical-stage biopharmaceutical company with a proprietary synthetic biology…
Read More...

Gilead Sciences, Inc. and Merus N.V. announced a research collaboration, option and license agreement to discover novel dual tumor-associated antigens (TAA) targeting trispecific…
Read More...

The European Medicines Agency (EMA) has validated two marketing authorisation applications (MAAs) for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan (Dato-DXd) in two types of…
Read More...

AbbVie Inc. and OSE Immunotherapeutics SA announced a strategic partnership to develop OSE-230, a monoclonal antibody designed to resolve chronic and severe inflammation, currently in…
Read More...

AbbVie Inc. and Tentarix Biotherapeutics announced a multi-year collaboration focused on the discovery and development of conditionally-active, multi-specific biologic candidates in…
Read More...